JP2009519339A - 筋細胞増殖及び分化を調節するマイクロｒｎａ - Google Patents

筋細胞増殖及び分化を調節するマイクロｒｎａ Download PDF

Info

Publication number
JP2009519339A
JP2009519339A JP2008545718A JP2008545718A JP2009519339A JP 2009519339 A JP2009519339 A JP 2009519339A JP 2008545718 A JP2008545718 A JP 2008545718A JP 2008545718 A JP2008545718 A JP 2008545718A JP 2009519339 A JP2009519339 A JP 2009519339A
Authority
JP
Japan
Prior art keywords
mir
mirna
gene
muscle
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519339A5 (https=
Inventor
ワン ダジ
チェン ジャンフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2009519339A publication Critical patent/JP2009519339A/ja
Publication of JP2009519339A5 publication Critical patent/JP2009519339A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008545718A 2005-12-12 2006-12-12 筋細胞増殖及び分化を調節するマイクロｒｎａ Pending JP2009519339A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74954405P 2005-12-12 2005-12-12
PCT/US2006/047255 WO2007070483A2 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013027633A Division JP5796027B2 (ja) 2005-12-12 2013-02-15 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013253829A Division JP5740460B2 (ja) 2005-12-12 2013-12-09 筋細胞増殖及び分化を調節するマイクロｒｎａ

Publications (2)

Publication Number Publication Date
JP2009519339A true JP2009519339A (ja) 2009-05-14
JP2009519339A5 JP2009519339A5 (https=) 2010-01-14

Family

ID=38163464

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008545718A Pending JP2009519339A (ja) 2005-12-12 2006-12-12 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013027633A Expired - Fee Related JP5796027B2 (ja) 2005-12-12 2013-02-15 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013253829A Expired - Fee Related JP5740460B2 (ja) 2005-12-12 2013-12-09 筋細胞増殖及び分化を調節するマイクロｒｎａ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013027633A Expired - Fee Related JP5796027B2 (ja) 2005-12-12 2013-02-15 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013253829A Expired - Fee Related JP5740460B2 (ja) 2005-12-12 2013-12-09 筋細胞増殖及び分化を調節するマイクロｒｎａ

Country Status (14)

Country Link
US (3) US8431542B2 (https=)
EP (3) EP2671949A1 (https=)
JP (3) JP2009519339A (https=)
KR (2) KR101485071B1 (https=)
CN (2) CN104027818A (https=)
AU (1) AU2006326517B2 (https=)
BR (1) BRPI0619755A2 (https=)
CA (2) CA2903764A1 (https=)
DK (1) DK1969125T3 (https=)
ES (1) ES2387250T3 (https=)
NZ (3) NZ602571A (https=)
PL (1) PL1969125T3 (https=)
PT (1) PT1969125E (https=)
WO (1) WO2007070483A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542921A (ja) * 2010-09-13 2013-11-28 エスエヌユー アールアンドディービー ファウンデーション ｍｉＲＮＡをターゲットとした神経変性疾患の治療
JP2014503192A (ja) * 2010-11-05 2014-02-13 ミラゲン セラピューティクス 塩基修飾オリゴヌクレオチド
WO2018070510A1 (ja) * 2016-10-13 2018-04-19 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
JP2020534349A (ja) * 2017-08-18 2020-11-26 クラミス シーオー., エルティーディー.Curamys Co., Ltd. 筋肉疾患および神経筋肉疾患の予防、治療または診断のためのｍｉＲ−１８ｂの用途
JP2021505176A (ja) * 2017-12-08 2021-02-18 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法
US11597930B2 (en) 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
JP2023515672A (ja) * 2020-03-02 2023-04-13 テナヤ セラピューティクス， インコーポレイテッド 心筋細胞発現マイクロｒｎａによる遺伝子ベクター制御

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877557A2 (en) * 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
KR101485071B1 (ko) 2005-12-12 2015-01-26 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 마이크로 ｒｎａ를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 ｒｎａ 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
GB2440782A (en) * 2006-08-04 2008-02-13 Cesare Peschle Uses and compositions comprising miRNAs
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
CN107129957A (zh) * 2007-06-29 2017-09-05 北京强新生物科技有限公司 促使长dsRNA可用于哺乳动物和其他所选动物细胞中的基因寻靶
EP2182969B1 (en) * 2007-07-31 2016-11-16 The Board of Regents of The University of Texas System A micro-rna family that modulates fibrosis and uses thereof
EP2187896B1 (en) * 2007-07-31 2016-01-13 The Board of Regents of The University of Texas System Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction
CA2716343A1 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
EP2265291B1 (en) * 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2303292A4 (en) * 2008-06-09 2013-01-02 New York Medical College COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC
GB0811715D0 (en) * 2008-06-26 2008-07-30 Angeletti P Ist Richerche Bio Therapeutic agents
RU2515926C2 (ru) 2009-02-04 2014-05-20 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
WO2010136846A1 (en) * 2009-05-25 2010-12-02 Carola Ponzetto Differentiation therapy for sarcomas
US20130034850A1 (en) * 2010-02-26 2013-02-07 Natinal Center of Neurology and Psychiatry Marker for detecting myogenic disease and detection method using the same
CN103108953B (zh) * 2010-04-08 2015-04-08 京都府公立大学法人 使用来自体液的样本检测横纹肌肉瘤的方法
CA2804791C (en) 2010-07-08 2019-07-30 Duke University Direct reprogramming of cells to cardiac myocyte fate
EP2638158A4 (en) * 2010-11-11 2015-07-15 Univ Miami COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY
KR20140004646A (ko) 2010-12-15 2014-01-13 미라젠 세러퓨틱스 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
AU2012252165A1 (en) 2011-05-09 2013-03-21 Cambridge Enterprise Limited Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
CA2840222A1 (en) * 2011-07-01 2013-01-10 Board Of Regents, The University Of Texas System Compositions and methods for treating skeletal myopathy
WO2013007874A1 (en) * 2011-07-12 2013-01-17 Mart Saarma A transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene.
EP2755663A4 (en) 2011-09-13 2015-10-07 Ottawa Hospital Res Inst MicroRNA Inhibitors
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014151835A1 (en) 2013-03-15 2014-09-25 Miragen Therapeutics, Inc Locked nucleic acid inhibitor of mir-145 and uses thereof
DK2970968T3 (en) 2013-03-15 2018-03-05 Miragen Therapeutics Inc CONNECTED BICYCLIC Nucleosides
WO2014201254A1 (en) * 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
CN103710387B (zh) * 2013-12-25 2015-10-14 天津农学院 一种促进牛骨骼肌卫星细胞体外增殖的方法
JP6566536B2 (ja) * 2014-06-16 2019-08-28 国立大学法人山口大学 フォワードプライマー
CN104498497A (zh) * 2014-12-10 2015-04-08 山东农业大学 一种与奶山羊乳腺上皮细胞凋亡相关的miRNA及其在奶山羊育种中的应用
US10620109B2 (en) 2015-01-14 2020-04-14 Kyoto University Method for selecting skeletal muscle progenitor cell
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
CN104877960B (zh) * 2015-06-01 2017-09-19 东北农业大学 miR‑2400显著促进牛骨骼肌卫星细胞增殖的生物功能
CN105713972A (zh) * 2016-03-16 2016-06-29 上海中医药大学 miRNA在制备药物性心脏病生物标志物中的用途
CN106399473B (zh) * 2016-08-23 2019-12-06 南京大学 检测和评价力量训练效果的miRNA标志物或其组合及其应用
US10626395B2 (en) 2016-10-27 2020-04-21 The General Hospital Corporation Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
CN108324946B (zh) * 2017-01-20 2022-02-18 上海市东方医院 miRNA708、和/或301簇的微小RNA在改善心脏功能方面的应用
CN107096030A (zh) * 2017-03-20 2017-08-29 天津农学院 一种利用miR‑143抑制剂延缓小鼠失神经后肌肉萎缩的方法
WO2018187523A2 (en) * 2017-04-05 2018-10-11 University Of Cincinnati Promotion of cardiomyocyte proliferation and regenerative treatment of the heart by inhibition of microrna-128
WO2019035690A1 (ko) * 2017-08-18 2019-02-21 서울대학교병원 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
KR20200131287A (ko) * 2018-03-14 2020-11-23 베스 이스라엘 데코니스 메디칼 센터 마이크로-rna 22의 억제제
CN108690846A (zh) * 2018-04-17 2018-10-23 上海大学 抑制MiR-29b基因表达的应用
CN108823209B (zh) * 2018-07-18 2021-04-09 华中农业大学 骨骼肌特异性启动子及应用
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
CN111041052B (zh) * 2019-12-30 2021-05-28 嘉兴学院 mir-206在抑制猪脂肪细胞内的甘油三酯生成以及瘦肉猪育种中的应用
CN112266912A (zh) * 2020-10-22 2021-01-26 上海大学 靶向miR-29b的gRNA、AAV8-CRISPR/Cas9系统及其应用
WO2023034966A1 (en) * 2021-09-03 2023-03-09 The University Of North Carolina At Chapel Hill Compositions and methods of using the same for treating disorders associated with thymosin βeta 4
CN114480672B (zh) * 2022-02-22 2023-08-15 青岛农业大学 一种通过miR-145筛选高产肉率碱地黑牛的方法
CN114748497B (zh) * 2022-04-27 2024-10-18 广州市妇女儿童医疗中心 一种调控子宫肌收缩的miRNA分子miR-206及其应用
CN115181722B (zh) * 2022-08-30 2024-06-11 江苏农牧科技职业学院 一种鹅骨骼肌卫星细胞的体外分离和培养方法
CN117511884B (zh) * 2023-12-06 2024-06-11 中国农业科学院兰州畜牧与兽药研究所 Rtl1在抑制牦牛成肌细胞分化中的应用
KR20250173053A (ko) * 2024-05-31 2025-12-10 충남대학교산학협력단 전구체 miRNA를 포함하는 근육 감소 또는 근육 위축 예방, 개선 또는 치료용 조성물
KR20250173054A (ko) * 2024-05-31 2025-12-10 충남대학교산학협력단 전구체 miRNA를 포함하는 근육 감소 또는 근육 위축 진단용 바이오마커 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076622A2 (en) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803782B2 (en) * 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US20050124566A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP2447370B1 (en) * 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
SE0300500L (sv) * 2003-02-26 2003-11-18 Scania Cv Publ Kraftöverföring med från en huvudväxel skild rangeväxel
EP2302055B1 (en) * 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP1877557A2 (en) * 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
KR101485071B1 (ko) 2005-12-12 2015-01-26 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 마이크로 ｒｎａ를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 ｒｎａ 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076622A2 (en) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012041773; ＺＨＡＯ，Ｙ．　ｅｔ　ａｌ: 'Ｓｅｒｕｍ　ｒｅｓｐｏｎｓｅ　ｆａｃｔｏｒ　ｒｅｇｕｌａｔｅｓ　ａ　ｍｕｓｃｌｅ-ｓｐｅｃｉｆｉｃ　ｍｉｃｒｏＲＮＡ　ｔｈａｔ　ｔａｒｇｅｔｓ　Ｈａｎｄ２　ｄｕｒｉｎｇ　ｃａｒｄｉｏｇｅｎｅｓｉｓ' Ｎａｔｕｒｅ Ｖｏｌ．４３６，　Ｎｏ．７０４８, 2005, ｐ．２１４-２０ *
JPN6012041774; ＺＨＡＯ，Ｘ．　ｅｔ　ａｌ: 'Ｒｅｇｕｌａｔｉｏｎ　ｏｆ　ＭＥＦ２　ｂｙ　ｈｉｓｔｏｎｅ　ｄｅａｃｅｔｙｌａｓｅ　４-　ａｎｄ　ＳＩＲＴ１　ｄｅａｃｅｔｙｌａｓｅ-ｍｅｄｉａｔｅｄ　ｌｙｓｉｎｅ　ｍｏｄｉｆｉｃａｔｉｏｎｓ' Ｍｏｌ　Ｃｅｌｌ　Ｂｉｏｌ Ｖｏｌ．２５，　Ｎｏ．１９, 2005, ｐ．８４５６-６４ *
JPN6012041775; ＳＯＫＯＬ，Ｎ．Ｓ．　ｅｔ　ａｌ: 'Ｍｅｓｏｄｅｒｍａｌｌｙ　ｅｘｐｒｅｓｓｅｄ　Ｄｒｏｓｏｐｈｉｌａ　ｍｉｃｒｏＲＮＡ-１　ｉｓ　ｒｅｇｕｌａｔｅｄ　ｂｙ　Ｔｗｉｓｔ　ａｎｄ　ｉｓ　ｒｅｑｕｉｒｅｄ　ｉｎ　ｍｕｓｃｌｅｓ　ｄｕｒｉｎｇ' Ｇｅｎｅｓ　Ｄｅｖ Ｖｏｌ．１９，　Ｎｏ．１９, 2005, ｐ．２３４３-５４ *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542921A (ja) * 2010-09-13 2013-11-28 エスエヌユー アールアンドディービー ファウンデーション ｍｉＲＮＡをターゲットとした神経変性疾患の治療
JP2014503192A (ja) * 2010-11-05 2014-02-13 ミラゲン セラピューティクス 塩基修飾オリゴヌクレオチド
US11655469B2 (en) 2016-03-07 2023-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MicroRNAs and methods of their use
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
JP7005020B2 (ja) 2016-10-13 2022-02-10 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
US10934543B2 (en) 2016-10-13 2021-03-02 National Center Of Neurology And Psychiatry Inducer of muscle differentiation
JPWO2018070510A1 (ja) * 2016-10-13 2019-08-08 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
WO2018070510A1 (ja) * 2016-10-13 2018-04-19 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
JP2020534349A (ja) * 2017-08-18 2020-11-26 クラミス シーオー., エルティーディー.Curamys Co., Ltd. 筋肉疾患および神経筋肉疾患の予防、治療または診断のためのｍｉＲ−１８ｂの用途
US11286484B2 (en) 2017-08-18 2022-03-29 Curamys Co., Ltd. Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease
US11891604B2 (en) 2017-08-18 2024-02-06 Curamys Co., Ltd. Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease
JP2021505176A (ja) * 2017-12-08 2021-02-18 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法
JP7279953B2 (ja) 2017-12-08 2023-05-23 ユニバーシティ オブ ワシントン カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法
JP2023515672A (ja) * 2020-03-02 2023-04-13 テナヤ セラピューティクス， インコーポレイテッド 心筋細胞発現マイクロｒｎａによる遺伝子ベクター制御
US11597930B2 (en) 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US11795459B2 (en) 2020-04-02 2023-10-24 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US12104157B2 (en) 2020-04-02 2024-10-01 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides

Also Published As

Publication number Publication date
NZ593688A (en) 2013-01-25
CN101448942A (zh) 2009-06-03
EP2497827A1 (en) 2012-09-12
US8431542B2 (en) 2013-04-30
KR101485071B1 (ko) 2015-01-26
WO2007070483A9 (en) 2011-06-16
NZ602571A (en) 2014-03-28
EP1969125B1 (en) 2012-06-13
WO2007070483A3 (en) 2008-07-24
AU2006326517A1 (en) 2007-06-21
CN101448942B (zh) 2014-04-23
NZ569738A (en) 2012-03-30
EP2671949A1 (en) 2013-12-11
US20130225665A1 (en) 2013-08-29
BRPI0619755A2 (pt) 2011-10-18
WO2007070483A2 (en) 2007-06-21
EP1969125A4 (en) 2010-10-20
US20100292297A1 (en) 2010-11-18
JP2014094943A (ja) 2014-05-22
PL1969125T3 (pl) 2012-11-30
JP2013126996A (ja) 2013-06-27
CA2634046A1 (en) 2007-06-21
JP5740460B2 (ja) 2015-06-24
KR20080080177A (ko) 2008-09-02
US20130225658A1 (en) 2013-08-29
EP1969125A2 (en) 2008-09-17
JP5796027B2 (ja) 2015-10-21
DK1969125T3 (da) 2012-07-23
ES2387250T3 (es) 2012-09-19
CN104027818A (zh) 2014-09-10
AU2006326517B2 (en) 2013-02-21
US9072764B2 (en) 2015-07-07
CA2903764A1 (en) 2007-06-21
KR20140130562A (ko) 2014-11-10
PT1969125E (pt) 2012-08-16

Similar Documents

Publication Publication Date Title
JP5740460B2 (ja) 筋細胞増殖及び分化を調節するマイクロｒｎａ
US10612026B2 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
Yan et al. Dynamic expression of microRNA-127 during porcine prenatal and postnatal skeletal muscle development
AU2013202293B2 (en) MicroRNAs that regulate muscle cell proliferation and differentiation
US20100305195A1 (en) microrna mediator of cardiomyopathy and heart failure
HK1192280A (en) Micro-rna mir-145 that regulate muscle cell proliferation and differentiation
MX2008007552A (es) Microacidos ribonucleicos que regulan la proliferacion y diferenciacion de celulas musculares
Guess Characterization of microRNA Function During Skeletal Myogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140106